Pages that link to "Q40568614"
Jump to navigation
Jump to search
The following pages link to Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells (Q40568614):
Displaying 50 items.
- The role of Src in solid tumors (Q24616659) (← links)
- Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies (Q24645225) (← links)
- Systemic therapies for pancreatic cancer--the role of pharmacogenetics (Q27021716) (← links)
- Novel advances in pancreatic cancer treatment (Q28282794) (← links)
- Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway (Q28468471) (← links)
- Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis (Q30163857) (← links)
- A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. (Q33404541) (← links)
- Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy (Q33956574) (← links)
- Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. (Q34203648) (← links)
- Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma (Q34322085) (← links)
- Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells (Q34795689) (← links)
- Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth (Q34812100) (← links)
- The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. (Q34966503) (← links)
- Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model (Q35088031) (← links)
- Improved angiostatic activity of dasatinib by modulation with hydrophobic chains (Q35178869) (← links)
- Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells (Q35184278) (← links)
- Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma (Q35456086) (← links)
- The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma (Q35956062) (← links)
- Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer (Q36033055) (← links)
- Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis (Q36253834) (← links)
- Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine (Q36429931) (← links)
- Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells (Q36447737) (← links)
- Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation (Q36579884) (← links)
- The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors (Q36598516) (← links)
- Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells (Q36615085) (← links)
- The Src signaling pathway: a potential target in melanoma and other malignancies (Q36675509) (← links)
- The molecular biology of pancreatic cancer (Q37153303) (← links)
- Targeting Src in endometriosis-associated ovarian cancer (Q37224282) (← links)
- Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress (Q37259527) (← links)
- New treatment options for advanced pancreatic cancer (Q37345841) (← links)
- Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (Q37362851) (← links)
- Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity (Q37381557) (← links)
- SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma (Q37509699) (← links)
- Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol (Q37601058) (← links)
- A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance (Q37612692) (← links)
- Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors (Q37613072) (← links)
- Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression (Q37625252) (← links)
- The dual kinase complex FAK-Src as a promising therapeutic target in cancer (Q37771259) (← links)
- Challenges of drug resistance in the management of pancreatic cancer (Q37799830) (← links)
- Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer—A review (Q37853945) (← links)
- Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge (Q37994505) (← links)
- Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. (Q38469320) (← links)
- MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. (Q38804384) (← links)
- Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action (Q38818048) (← links)
- Antitumor activity of miR-1280 in melanoma by regulation of Src. (Q38959078) (← links)
- Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells (Q39146859) (← links)
- ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells (Q39169106) (← links)
- Molecular predictors of gemcitabine response in pancreatic cancer (Q39250668) (← links)
- Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach (Q39283216) (← links)
- The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells (Q39331157) (← links)